Drug Search Results
More Filters [+]

Larotrectinib

Alternative Names: larotrectinib, loxo-101, vitrakvi, BAY2757556, BAY-2757556, BAY 2757556
Latest Update: 2024-09-19
Latest Update Note: Clinical Trial Update

Product Description

Larotrectinib is used to treat a certain type of solid tumors in adults and children 1 month of age and older that have spread to other parts of the body or cannot be treated successfully with surgery. This medication is used only if there are no other treatments available and the tumors have worsened after receiving other treatments. Larotrectinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that tells the cancer cells to multiply. This may help slow the growth of tumors. (Sourced from: https://medlineplus.gov/druginfo/meds/a619006.html)

Mechanisms of Action: TRKA Inhibitor,TRKB Inhibitor,TRKC Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Colombia | Croatia | Cyprus | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Kingdom | United States

Approved Indications: Oncology Solid Tumor Unspecified | Oncology Unspecified

Known Adverse Events: Dizziness | Constipation | Diarrhea

Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Larotrectinib

Countries in Clinic: China, Czech Republic, Denmark, France, Germany, Ireland, Italy, Japan, Netherlands, Portugal, Spain, Sweden, United States

Active Clinical Trial Count: 7

Highest Development Phases

Phase 2: Central Nervous System Cancer|Lymphoma, Non-Hodgkin|Multiple Myeloma|Oncology Solid Tumor Unspecified|Thyroid Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

20290

P2

Active, not recruiting

Central Nervous System Cancer

2026-09-01

TAPUR

P2

Recruiting

Multiple Myeloma|Lymphoma, Non-Hodgkin

2026-06-30

20289

P2

Active, not recruiting

Oncology Solid Tumor Unspecified

2025-10-31

NCT05783323

P2

Recruiting

Thyroid Cancer

2024-10-01

Recent News Events